| [1] |
Chagas AL, Felga GEG, Diniz MA, et al.Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival[J]．Eur J Gastroenterol Hepatol，2019，31(9)：1148-1156.
|
| [2] |
Foerster F, Hoppe－Lotichius M, Vollmar J，et al.Long－term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]．United European Gastroenterol J, 2019，7(6)：838-849.
|
| [3] |
Sanduzzi－Zamparelli M, Díaz－Gonzalez ？, Reig M．New Systemic Treatments in Advanced Hepatocellular Carcinoma[J]．Liver Transpl，2019，25(2)：311-322.
|
| [4] |
de’Angelis N, Landi F, Carra MC，et al.Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review[J]．World J Gastroenterol，2015，21(39)：11185-11198.
|
| [5] |
Bruix J, Qin S, Merle P，et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double－blind, placebo－controlled, phase 3 trial[J]．Lancet，2017，389(10064)：56-66.
|
| [6] |
Lerut J, Lesari S, Foguenne M, et al.Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression？[J]．Transl Gastroenterol Hepatol, 2017, 2：80.
|
| [7] |
Tarantino G, Magistri P, Ballarin R，et al.Oncological Impact of M－Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature[J]．Front Pharmacol，2016，7：387.
|
| [8] |
Kumari R, Sahu MK, Tripathy A，et al.Hepatocellular carcinoma treatment: hurdles, advances and prospects[J]．Hepat Onco，2018，5(2)：HEP08.
|
| [9] |
Teufel M, Seidel H, Köchert K，et al.Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology[J].2019，156(6)：1731-1741.
|
| [10] |
Liu S, Du Y, Ma H，et al.Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging[J]．Cancer Lett，2019，453：74-83.
|
| [11] |
Jindal A, Thadi A, Shailubhai K．Hepatocellular carcinoma: etiology, current and future drugs[J]．J Clin Exp Hepatol，2019，9(2)：221-232.
|
| [12] |
Grigg SE, Sarri GL, Gow PJ，et al.Systematic review with meta－analysis: sirolimus－ or everolimus－based immunosuppression following liver transplantation for hepatocellular carcinoma[J]．Aliment Pharmacol Ther，2019，49(10)：1260-1273.
|
| [13] |
Grigg SE, Sarri GL, Gow PJ，et al.Systematic review with meta－analysis: sirolimus－ or everolimus－based immunosuppression following liver transplantation for hepatocellular carcinoma[J]．Aliment Pharmacol Ther，2019，49(10)：1260-1273.
|
| [14] |
Mazzola A, Costantino A, Petta S，et al.Recurrence of hepatocellular carcinoma after liver transplantation: an update[J]．Future Oncol，2015，11(21)：2923-2936.
|
| [15] |
Cerrito L, Ponziani FR, Garcovich M，et al.Regorafenib: a promising treatment for hepatocellular carcinoma[J]．Expert Opin Pharmacother，2018，19(17)：1941-1948.
|
| [16] |
Cholongitas E, Mamou C, Rodríguez－Castro KI，et al.Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]．Transpl Int，2014，27(10)：1039-1049.
|